Latest Conference Articles

Ozanimod reduced ARR and showed marked reductions in T2 lesions compared with interferon β-1a for RMS.

Subgroup analysis revealed a greater improvement for patients with baseline visual impairment.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

Francisco Quintana, MD, spoke about his efforts to identify new drugs for treating multiple sclerosis and how reliable biomarkers are the biggest need in treating MS.

Nearly all patients with relapsing multiple sclerosis treated with ublituximab remained relapsed free after 24 weeks.

Ruth Ann Marrie, MD, PhD, FRCP, spoke about the prevalence of comorbidities in patients with MS, and how these patients are often overlooked and left out of clinical trials.

Martin Weber, MD, spoke about the role that B cells and antibodies play in the treatment of multiple sclerosis.

MD1003 led to a pseudo-atrophy phenomenon that was likely related to remyelination.

The EXPAND trial results supported the potential neuroprotective effects of siponimod.

Infections in immunocompromised patients continue to rise because of more enhanced diagnostics and increased cultures.

The CAPSTONE-1 trial demonstrated a new antiviral aimed to reduce flu symptoms with possible NDA submission.

The UN and WHO aim to reduce the burden of cholera globally by 90% reduction in deaths by 2030.

Since 2000 there's been a 30% overall reduction in malaria, however, a vaccine is needed as another tool.

Catch up on what you missed in how HIV affects the brain.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.

Treated in hospital settings, cUTI has been traditionally treated with quinolones due to a patient’s ability to transfer from IV to oral form when they’re discharged.

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

What expecting mothers with Zika virus should know.

The D/C/F/TAF combination tablet showed 2.5% virologic rebound and 94.9% virologic suppression in almost 800 patients.

As drug costs continue to rise, many are hoping generics will bring relief. But will they?

Antibiotics are not harmless drugs, but recent findings suggest that dentists may be prescribing them under that assumption.

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the current and future state of costs for HIV medications.

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the future for HIV drug prices.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about challenges of Hepatitis C treatment.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the current state and future of Hepatitis C.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the challenges treating co-infected HIV and HCV patients.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.

The drug is in phase 3 trials for CABP, and shows potential for pneumonia associated with S. aureas.

Patients with HIV are living longer. How does their condition affect the cognitive decline that comes with aging?

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the impact and potential for antivirals in the US.